Publisher

UNIVMEDUNIVMED

Journal Universa MedicinaUniversa Medicina Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is caused by B-cell hyperactivity, which stimulates the production of autoantibodies, leading to the formation of immune complexes and resulting in tissue damage. Increased B-cell activation is associated with disease activity in SLE. The cytokine B-cell Activating Factor (BAFF) and its soluble BAFF receptor (sBAFF-R) play a crucial role in B-cell activation and survival. Their serum levels may serve as potential biomarkers for SLE severity. This study aimed to compare serum levels of BAFF and sBAFF-R between SLE patients with mild, moderate, and severe disease activity.. . METHODS: A cross-sectional study was conducted involving 33 female SLE patients. Subjects were divided into mild, moderate, and severe disease activity groups. Disease activity was assessed using Mexican Systemic Lupus Erythematosus Disease Activity Index (MEX-SLEDAI) scores. Serum BAFF and sBAFF-R levels were measured using ELISA. Data were analyzed using the Kruskal–Wallis and Mann-Whitney tests. A p-value < 0.05 was considered statistically significant.. . RESULTS: The median serum BAFF level in SLE patients was 0.51 ng/mL, and 4.66 ng/mL in sBAFF-R level.There was a statistically significant difference in serum BAFF and sBAFF-R levels between mild, moderate, and severe disease activity among SLE patients (p<0.0001).

Conclusion

Increased serum levels of BAFF and sBAFF-R may influence disease activity in SLE.Serum concentrations of BAFF and sBAFF-R were found to be associated with disease severity, including mild, moderate, and severe categories.These findings suggest that serum BAFF and sBAFF-R levels may serve as potential biomarkers for assessing SLE activity.

Future Research

Penelitian lebih lanjut perlu dilakukan untuk mengeksplorasi peran BAFF dan sBAFF-R sebagai prediktor respons terhadap terapi pada pasien SLE, dengan mempertimbangkan variasi genetik dan faktor imunologi lainnya. Studi longitudinal yang melibatkan pengukuran serial BAFF dan sBAFF-R dapat memberikan pemahaman yang lebih baik tentang perubahan biomarker seiring waktu dan hubungannya dengan perkembangan penyakit serta efektivitas pengobatan. Selain itu, penelitian yang bertujuan untuk mengembangkan dan memvalidasi nilai ambang batas (cut-off values) yang spesifik untuk BAFF dan sBAFF-R dalam mengklasifikasikan tingkat aktivitas penyakit SLE sangat diperlukan, terutama dalam konteks klinis di mana pengujian imunologi komprehensif mungkin terbatas. Penelitian ini akan membantu mengoptimalkan penggunaan biomarker ini sebagai alat bantu diagnostik dan pemantauan penyakit yang lebih akurat dan terjangkau.

References

1. Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and... doi.org/10.1002/acr.24431Systemic Lupus Erythematosus Targeted Literature Review of the Epidemiology Current Treatment and doi 10 1002 acr 24431
2. Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and... onlinelibrary.wiley.com/doi/10.1002/cti2.1047Analysis of serum B cellyAAAaactivating factor from the tumor necrosis factor family BAFF and onlinelibrary wiley doi 10 1002 cti2 1047

Metadata

File size	472.83 KB
Pages	9
DMCA	Report